These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36877549)

  • 1. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
    Chow A; Silkiss RZ
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ototoxicity and Teprotumumab.
    Highland J; Gordon S; Reddy D; Patel N
    Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Experience With Teprotumumab in Patients With Dysthyroid Optic Neuropathy.
    Tamhankar MA; Pradeep T; Chen Y; Briceño CA
    J Neuroophthalmol; 2024 Mar; 44(1):74-79. PubMed ID: 37751310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
    Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
    Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
    Radulovich N; Van Brummen A; Chambers C; Zhang M
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 17. Teprotumumab for Thyroid-Associated Ophthalmopathy.
    Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
    N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
    Chu M; Sung J; Song M; Song A; Song J
    J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab for the treatment of thyroid eye disease.
    Ju Y; Yang J
    Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.